As part of the company’s fourth-quarter 2017 earnings report, Paris-based Sanofi released a pipeline update showing it plans to halt several mid-stage drug programs.

Novartis hired Elizabeth Barrett, Pfizer’s head of oncology, to replace Bruno Strigini, the chief executive officer of Novartis Oncology who retired at the end of 2017.

Researchers at Stanford University School of Medicine with the National Cancer Institute have identified another cancer-surface molecule, CD22, and begun trials on B-cell acute lymphoblastic leukemia patients using an immuno-oncology approach similar to CAR-T.

French cell therapy specialist Cellectis, which is developing a gene-modified cancer treatment, was forced to suspend testing following a patient death.

Novartis CEO Joe Jimenez will step down on Feb. 1, 2018, and hand over the top leadership role of the Swiss company to drug development chief Vas Narasimhan.

Novartis’s new gene-modifying cancer therapy’s $475,000-per-patient sticker price has drawn fire from advocate groups calling for cheaper drugs, but analysts said the Swiss drugmaker could initially struggle to break even.

Novartis’ anticipated leukemia treatment Kymriah is the first gene therapy to receive U.S. marketing clearance.

The U.S. Food and Drug Administration approved Pfizer Inc.’s rare blood cancer drug Besponsa with a boxed warning.

Vitamin C may “tell” faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers. This is the finding of a study led by researchers from Perlmutter Cancer Center at NYU Langone Health, and published online August 17, 2017, in the journal Cell.

The biotech industry did OK in July 2017. The NYSE ARCA Biotech Index and the iShares NASDAQ Biotechnology Index (ETF) grew about 1.9 percent and 2.9 percent, respectively last month. There have been 26 new molecular entity approvals so far this year. With that figure in mind, here are eight companies looking at PDUFA dates in August 2017.